B+
Bull case
25%
Probability
Target price
$17.00
Analysis reference price unavailable
Analysis 2026-05-16 · RankAlpha Sentiment Codex
CLPT
ClearPoint NeuroDNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
40%
Probability
Target price
$11.00
Analysis reference price unavailable
Analysis 2026-05-16 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-05-16 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-16
Recent news sentiment (30D)
-0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+42.3
Score
AI commentary
Post-earnings tone is mixed but cautious. The company source showed strong growth and maintained guidance, yet trusted market coverage highlighted an EPS miss and only modest consensus revenue performance. A secondary earnings feed showed shares down about 5% immediately after the release, and the May 15 anchor price of $11.64 suggests the initial skepticism had not fully reversed by T+3. Analyst-revision visibility remains thin, which argues for a monitoring stance rather than a strong post-print upgrade.
RankAlpha Sentiment Codex - 2026-05-16
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-15catalystQ1 print showed strong growth but did not clearly change the monitoring thesisMedium impact
Q1 2026 revenue was $12.1 million, up 43% year over year, with gross margin at 64%; management kept 2026 revenue outlook at $52.0-$56.0 million and said IRRAS integration synergies should reduce cash burn in 2H26, but the company still used about $8.0 million of operating cash in Q1 and remains loss-making [#8-K-2026-05-13] [#10-Q-2026-05-13].
2026-09-30eventNew product and geography milestones need to convert into paid proceduresHigh impact
Management highlighted FDA-cleared Velocity Alpha's first clinical use and a Health Canada device license for the navigation system, with first Canadian cases scheduled; the next proof point is whether these milestones turn into recurring case volume and equipment placements rather than one-off announcements [#8-K-2026-05-13].
2026-12-31catalystBiopharma-partner and installed-base expansion can support growth, but timing is hard to underwriteHigh impact
ClearPoint said its activated installed base now exceeds 175 global centers and that it is progressing work across more than 60 active biopharma partners; that creates real optionality for procedure growth and future delivery revenue, but milestone timing remains dependent on partner funding, enrollment, regulatory progress, and adoption [#8-K-2026-05-13].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-16 • Updated nightlySource: Internal modelMethodology